GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Gross Profit

VRAX (Virax Biolabs Group) Gross Profit : $0.03 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Gross Profit?

Virax Biolabs Group's gross profit for the six months ended in Sep. 2024 was $-0.01 Mil. Virax Biolabs Group's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $0.03 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Virax Biolabs Group's gross profit for the six months ended in Sep. 2024 was $-0.01 Mil. Virax Biolabs Group's Revenue for the six months ended in Sep. 2024 was $0.01 Mil. Therefore, Virax Biolabs Group's Gross Margin % for the quarter that ended in Sep. 2024 was -120.00%.

Virax Biolabs Group had a gross margin of -120.00% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage

During the past 5 years, the highest Gross Margin % of Virax Biolabs Group was 46.00%. The lowest was -11.11%. And the median was 12.72%.


Virax Biolabs Group Gross Profit Historical Data

The historical data trend for Virax Biolabs Group's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Gross Profit Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
0.05 -0.01 - - 0.05

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.01 0.04 -0.01

Competitive Comparison of Virax Biolabs Group's Gross Profit

For the Biotechnology subindustry, Virax Biolabs Group's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Gross Profit distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Gross Profit falls into.


;
;

Virax Biolabs Group Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Virax Biolabs Group's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=0.156 - 0.105
=0.05

Virax Biolabs Group's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=0.005 - 0.011
=-0.01

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.03 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Virax Biolabs Group's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=-0.01 / 0.005
=-120.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Virax Biolabs Group  (NAS:VRAX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Virax Biolabs Group had a gross margin of -120.00% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Virax Biolabs Group Gross Profit Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Virax Biolabs Group Business Description

Traded in Other Exchanges
N/A
Address
Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.